Bronchodilators Market: By Drug Class (Phosphodiesterase Inhibitors, Anticholinergics, Sympathomimetics, Combination Drugs), By Route of Administration (Oral, Parenteral, Inhalation), By Disease Type (Asthma, Chronic Obstructive Pulmonary Disease (COPD), Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), and Geography  

Purchase Option

$ 4400
$ 6600
$ 8900

Bronchodilators Market size was valued at USD 34.6 billion in 2022 and is poised to grow at a CAGR of 5.4% from 2023-2029. The global market provides a detailed overview of the global bronchodilators market, and that can be segmented by drug class, route of administration, disease type, and by distribution channel. By drug class, the global bronchodilators market has been segmented into Phosphodiesterase Inhibitors, Anticholinergics, Sympathomimetics, and Combination Drugs. The Anticholinergics Inhibitors segment is likely to be the largest and fastest-growing segment in terms of drug class in 2021 and is expected to maintain the trend in the forecasted years. It is attributed to its wide application to treat chronic obstructive pulmonary disease. Based on route of administration, the global bronchodilators market is segmented into Oral Care Products, Parenteral, and Inhalation. Among these, the Oral segment is expected to have the fastest-growing market during the forecast period 2022-2028. Based on disease type, the global bronchodilators market is segmented into Asthma, Chronic Obstructive Pulmonary Disease (COPD), and Others. The Asthma segment accounts for the largest share in 2021. Hosted segment is the second-largest share during the forecast period 2022-2028 period according to precision business insights. It is attributed to the increasing prevalence of asthma across the world. Based on distribution channel, the global bronchodilators market is segmented into Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies. The Hospital Pharmacies segment accounts for the largest share in 2021. Hospital pharmacies has very large patient base and prescribed medicines for hospital patients are boosting the growth in this segment. Bronchodilators are agents dilate the bronchioles and bronchi to improve the airflow to the lungs.  These are commonly used in the treatment of obstructive lung diseases such as chronic obstructive pulmonary disease (COPD) emphysema, asthma, and other lung diseases. Bronchodilators are majorly classified based on their duration of action such as short-acting and long-acting.

Bronchodilators Market Key Developments:
  • In Oct 2022, AeroRx Therapeutics partnered with HCmed Innovations to develop a new therapeutic combination of different classes of bronchodilators.

Global Bronchodilators Market Summary

Study Period

2024-2030

Base Year

2023

CAGR

5.4%

Largest Market

North America

Fastest Growing Market

Europe
Bronchodilators Market Dynamics

Increase in the aging population coupled with rise in prevalence of various lung diseases such as asthma and COPD are anticipated to propel the market growth over the forecast years.

Key Features of the Reports

  • The report provides granular level information about the market size, regional market share, historic market (2018 to 2022), and forecast (2023 to 2029)
  • The report covers in-detail insights about the competitor's overview, company share analysis, key market developments, and key strategies
  • The report outlines drivers, restraints, unmet needs, and trends that are currently affecting the market
  • The report tracks recent innovations, key developments, and startups details that are actively working in the market
  • The report provides a plethora of information about market entry strategies, regulatory framework, and reimbursement scenario
  • The report analyses the impact of the socio-political environment through PESTLE Analysis and competition through Porters Five Force Analysis in addition to recent technology advancements and innovations in the market

Global Bronchodilators Market Segmentation

By Drug Class
  • Phosphodiesterase Inhibitors
  • Anticholinergics
  • Sympathomimetics
  • Non-Selective Adrenergic Agonists
  • Non-Selective Beta-2 Agonists
  • Selective Beta-2 Agonists
  • Combination Drugs
By Administration
  • Oral
  • Parenteral
  • Inhalation
By Disease Type
  • Asthma
  • Chronic Obstructive Pulmonary Disease (COPD)
  • Others
By Distribution Channel
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

Frequently Asked Questions

The bronchodilators market size was valued at USD 34.6 billion in 2022

The bronchodilators market key players are: Hoffmann La Roche Ltd. (Switzerland) Boehringer Ingelheim GmbH (Germany) Novartis AG (Switzerland) Merck & Co. Inc. (U.S.) AstraZeneca plc (U.K.) GlaxoSmithKline (U.S.) Aquinox Pharmaceuticals (Canada) MediciNova, Inc. (U.S.) Gilead Sciences, Inc. (U.S.) Biomarck Pharmaceuticals (U.S.)

The slam technology market bronchodilators market has been classified into North America, Asia Pacific, Europe, Latin America, Middle East and Africa, and the rest of MEA.

1. Executive Summary
2. Global Bronchodilators Market Introduction 
2.1.Global Bronchodilators Market  - Taxonomy
2.2.Global Bronchodilators Market  - Definitions
2.2.1.Drug Class
2.2.2.Administration
2.2.3.Disease Type
2.2.4.Distribution Channel
2.2.5.Region
3. Global Bronchodilators Market Dynamics
3.1. Drivers
3.2. Restraints
3.3. Opportunities/Unmet Needs of the Market
3.4. Trends
3.5. Product Landscape
3.6. New Product Launches
3.7. Impact of COVID 19 on Market
4. Global Bronchodilators Market Analysis, 2018 - 2022 and Forecast 2023 - 2029
4.1.  Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million)
4.2.  Year-Over-Year (Y-o-Y) Growth Analysis (%) 
4.3.  Market Opportunity Analysis 
5. Global Bronchodilators Market  By Drug Class, 2018 - 2022 and Forecast 2023 - 2029 (Sales Value USD Million)
5.1. Phosphodiesterase Inhibitors
5.1.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million)
5.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
5.1.3. Market Opportunity Analysis 
5.2. Anticholinergics
5.2.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million)
5.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
5.2.3. Market Opportunity Analysis 
5.3. Sympathomimetics
5.3.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million)
5.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
5.3.3. Market Opportunity Analysis 
5.4. Non-Selective Adrenergic Agonists
5.4.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million)
5.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
5.4.3. Market Opportunity Analysis 
5.5. Non-Selective Beta-2 Agonists
5.5.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million)
5.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
5.5.3. Market Opportunity Analysis 
5.6. Selective Beta-2 Agonists
5.6.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million)
5.6.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
5.6.3. Market Opportunity Analysis 
5.7. Combination Drugs
5.7.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million)
5.7.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
5.7.3. Market Opportunity Analysis 
6. Global Bronchodilators Market  By Administration, 2018 - 2022 and Forecast 2023 - 2029 (Sales Value USD Million)
6.1. Oral
6.1.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million)
6.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
6.1.3. Market Opportunity Analysis 
6.2. Parenteral
6.2.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million)
6.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
6.2.3. Market Opportunity Analysis 
6.3. Inhalation
6.3.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million)
6.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
6.3.3. Market Opportunity Analysis 
7. Global Bronchodilators Market  By Disease Type, 2018 - 2022 and Forecast 2023 - 2029 (Sales Value USD Million)
7.1. Asthma
7.1.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million)
7.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
7.1.3. Market Opportunity Analysis 
7.2. Chronic Obstructive Pulmonary Disease (COPD)
7.2.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million)
7.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
7.2.3. Market Opportunity Analysis 
7.3. Others
7.3.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million)
7.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
7.3.3. Market Opportunity Analysis 
8. Global Bronchodilators Market  By Distribution Channel, 2018 - 2022 and Forecast 2023 - 2029 (Sales Value USD Million)
8.1. Hospital Pharmacies
8.1.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million)
8.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
8.1.3. Market Opportunity Analysis 
8.2. Retail Pharmacies
8.2.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million)
8.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
8.2.3. Market Opportunity Analysis 
8.3. Online Pharmacies
8.3.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million)
8.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
8.3.3. Market Opportunity Analysis 
9. Global Bronchodilators Market  By Region, 2018 - 2022 and Forecast 2023 - 2029 (Sales Value USD Million)
9.1. North America
9.1.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million)
9.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
9.1.3. Market Opportunity Analysis 
9.2. Europe
9.2.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million)
9.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
9.2.3. Market Opportunity Analysis 
9.3. Asia Pacific (APAC)
9.3.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million)
9.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
9.3.3. Market Opportunity Analysis 
9.4. Middle East and Africa (MEA)
9.4.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million)
9.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
9.4.3. Market Opportunity Analysis 
9.5. Latin America
9.5.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million)
9.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
9.5.3. Market Opportunity Analysis 
10. North America Bronchodilators Market ,2018 - 2022 and Forecast 2023 - 2029 (Sales Value USD Million)
10.1. Drug Class Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
10.1.1.Phosphodiesterase Inhibitors
10.1.2.Anticholinergics
10.1.3.Sympathomimetics
10.1.4.Non-Selective Adrenergic Agonists
10.1.5.Non-Selective Beta-2 Agonists
10.1.6.Selective Beta-2 Agonists
10.1.7.Combination Drugs
10.2.  Administration Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
10.2.1.Oral
10.2.2.Parenteral
10.2.3.Inhalation
10.3.  Disease Type Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
10.3.1.Asthma
10.3.2.Chronic Obstructive Pulmonary Disease (COPD)
10.3.3.Others
10.4.  Distribution Channel Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
10.4.1.Hospital Pharmacies
10.4.2.Retail Pharmacies
10.4.3.Online Pharmacies
10.5.  Country Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
10.5.1.United States of America (USA)
10.5.2.Canada
11. Europe Bronchodilators Market ,2018 - 2022 and Forecast 2023 - 2029 (Sales Value USD Million)
11.1. Drug Class Analysis  and Forecast  by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
11.1.1.Phosphodiesterase Inhibitors
11.1.2.Anticholinergics
11.1.3.Sympathomimetics
11.1.4.Non-Selective Adrenergic Agonists
11.1.5.Non-Selective Beta-2 Agonists
11.1.6.Selective Beta-2 Agonists
11.1.7.Combination Drugs
11.2.  Administration Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
11.2.1.Oral
11.2.2.Parenteral
11.2.3.Inhalation
11.3.  Disease Type Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
11.3.1.Asthma
11.3.2.Chronic Obstructive Pulmonary Disease (COPD)
11.3.3.Others
11.4.  Distribution Channel Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
11.4.1.Hospital Pharmacies
11.4.2.Retail Pharmacies
11.4.3.Online Pharmacies
11.5.  Country Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
11.5.1.Germany
11.5.2.France
11.5.3.Italy
11.5.4.United Kingdom (UK)
11.5.5.Spain
11.5.6.Rest of EU
12. Asia Pacific (APAC) Bronchodilators Market ,2018 - 2022 and Forecast 2023 - 2029 (Sales Value USD Million)
12.1. Drug Class Analysis  and Forecast  by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
12.1.1.Phosphodiesterase Inhibitors
12.1.2.Anticholinergics
12.1.3.Sympathomimetics
12.1.4.Non-Selective Adrenergic Agonists
12.1.5.Non-Selective Beta-2 Agonists
12.1.6.Selective Beta-2 Agonists
12.1.7.Combination Drugs
12.2.  Administration Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
12.2.1.Oral
12.2.2.Parenteral
12.2.3.Inhalation
12.3.  Disease Type Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
12.3.1.Asthma
12.3.2.Chronic Obstructive Pulmonary Disease (COPD)
12.3.3.Others
12.4.  Distribution Channel Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
12.4.1.Hospital Pharmacies
12.4.2.Retail Pharmacies
12.4.3.Online Pharmacies
12.5.  Country Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
12.5.1.China
12.5.2.India
12.5.3.Australia and New Zealand (ANZ)
12.5.4.Japan
12.5.5.Rest of APAC
13.Middle East and Africa (MEA) Bronchodilators Market ,2018 - 2022 and Forecast 2023 - 2029 (Sales Value USD Million)
13.1. Drug Class Analysis  and Forecast  by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
13.1.1.Phosphodiesterase Inhibitors
13.1.2.Anticholinergics
13.1.3.Sympathomimetics
13.1.4.Non-Selective Adrenergic Agonists
13.1.5.Non-Selective Beta-2 Agonists
13.1.6.Selective Beta-2 Agonists
13.1.7.Combination Drugs
13.2.  Administration Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
13.2.1.Oral
13.2.2.Parenteral
13.2.3.Inhalation
13.3.  Disease Type Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
13.3.1.Asthma
13.3.2.Chronic Obstructive Pulmonary Disease (COPD)
13.3.3.Others
13.4.  Distribution Channel Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
13.4.1.Hospital Pharmacies
13.4.2.Retail Pharmacies
13.4.3.Online Pharmacies
13.5.  Country Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
13.5.1.GCC Countries
13.5.2.South Africa
13.5.3.Rest of MEA
14.Latin America Bronchodilators Market ,2018 - 2022 and Forecast 2023 - 2029 (Sales Value USD Million)
14.1. Drug Class Analysis  and Forecast  by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
14.1.1.Phosphodiesterase Inhibitors
14.1.2.Anticholinergics
14.1.3.Sympathomimetics
14.1.4.Non-Selective Adrenergic Agonists
14.1.5.Non-Selective Beta-2 Agonists
14.1.6.Selective Beta-2 Agonists
14.1.7.Combination Drugs
14.2.  Administration Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
14.2.1.Oral
14.2.2.Parenteral
14.2.3.Inhalation
14.3.  Disease Type Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
14.3.1.Asthma
14.3.2.Chronic Obstructive Pulmonary Disease (COPD)
14.3.3.Others
14.4.  Distribution Channel Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
14.4.1.Hospital Pharmacies
14.4.2.Retail Pharmacies
14.4.3.Online Pharmacies
14.5.  Country Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
14.5.1.Brazil
14.5.2.Mexico
14.5.3.Rest of LA
15. Competition Landscape
15.1.  Market Player Profiles (Introduction, Brand/Product Sales, Financial Analysis, Product Offerings, Key Developments, Collaborations, M & A, Strategies, and SWOT Analysis) 
15.2.1.Hoffmann La Roche Ltd. (Switzerland)
15.2.2.Boehringer Ingelheim GmbH (Germany)
15.2.3.Novartis AG (Switzerland)
15.2.4.Merck & Co. Inc. (U.S.)
15.2.5.AstraZeneca plc (U.K.)
15.2.6.GlaxoSmithKline (U.S.)
15.2.7.Aquinox Pharmaceuticals (Canada)
15.2.8.MediciNova, Inc. (U.S.)
15.2.9.Gilead Sciences, Inc. (U.S.)
15.2.10.Biomarck Pharmaceuticals (U.S.)
16. Research Methodology 
17. Appendix and Abbreviations 
  • Hoffmann La Roche Ltd. (Switzerland)
  • Boehringer Ingelheim GmbH (Germany)
  • Novartis AG (Switzerland)
  • Merck & Co. Inc. (U.S.)
  • AstraZeneca plc (U.K.)
  • GlaxoSmithKline (U.S.)
  • Aquinox Pharmaceuticals (Canada)
  • MediciNova, Inc. (U.S.)
  • Gilead Sciences, Inc. (U.S.)
  • Biomarck Pharmaceuticals (U.S.)

Adjacent Markets